BMS-2

CAS No. 888719-03-7

BMS-2( —— )

Catalog No. M21662 CAS No. 888719-03-7

BMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 179 In Stock
2MG 90 In Stock
5MG 151 In Stock
10MG 242 In Stock
25MG 454 In Stock
50MG 642 In Stock
100MG 927 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    BMS-2
  • Note
    Research use only, not for human use.
  • Brief Description
    BMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor.
  • Description
    BMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor.
  • In Vitro
    ——
  • In Vivo
    Animal Model:MiceDosage:5, 10 mg/kg Administration:IV, POResult:Showed extensive extravascular distribution and a favorable half-life.Animal Model:Nude mice Dosage:6.25, 12.5, 25 and 50 mg/kg Administration:PO, once a day Result:Showed antitumor activity in dose-dependet.
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    c-Met/HGFR
  • Recptor
    Met|FLT3|VEGFR2
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    888719-03-7
  • Formula Weight
    458.42
  • Molecular Formula
    C25H16F2N4O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (218.14 mM)
  • SMILES
    Fc1ccc(cc1)-n1cccc(C(=O)Nc2ccc(Oc3ccnc4[nH]ccc34)c(F)c2)c1=O
  • Chemical Name
    1-(4-Fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[23-b]pyridin-4-yloxy)phenyl]-2-oxopyridine-3-carboxamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Onartuzumab

    Onartuzumab (MetMAb) is a humanized anti-tyrosine kinase c-MET monovalent monoclonal antibody.

  • Glesatinib

    Glesatinib (MGCD-265) is a tyrosine kinase inhibitor that potently and selectively inhibits Met and Axl kinase.

  • AMG-458

    AMG-458 (AMG458) is a potent, selective, orally bioavailable c-Met inhibitor with Ki of 1.2 nM.